Segmentectomy should be considered as part of standard treatment for patients with
predominantly GGO NSCLC with a tumour size of 3 cm or less in diameter, including
GGO even if it exceeds 2 cm.
Sotorasib significantly increased progression-free survival and had a more favourable
safety profile, compared with docetaxel, in patients with advanced NSCLC with the
KRASG12C mutation and who had been previously treated with other anticancer drugs.
These updated, long-term data from CROWN show the durable benefit of lorlatinib over
crizotinib in patients with treatment-naive, ALK-positive non-small-cell lung cancer
and support the use of first-line lorlatinib in patients with and without baseline
brain metastases.
Cancer research is a crucial pillar for countries to deliver more affordable, higher
quality, and more equitable cancer care. Patients treated in research-active hospitals
have better outcomes than patients who are not treated in these settings. However,
cancer in Europe is at a crossroads. Cancer was already a leading cause of premature
death before the COVID-19 pandemic, and the disastrous effects of the pandemic on
early diagnosis and treatment will probably set back cancer outcomes in Europe by
almost a decade.
Improved models of care for cancer survivors thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.